[Fundamental studies and clinical evaluation of PC-904 in urinary tract infection (author's transl)].
Measurement of MICs of PC-904, CBPC and GM against 135 strains of Pseudomonas aeruginosa isolated from patients with urinary tract infections was performed. Susceptibility to PC-904 of Pseudomonas aeruginosa was found to be 3 approximately 7 times more sensitive than that to CBPC and as same as that to GM with inoculum size of 10(8)/ml and 10(6)/ml. Serum level of PC-904 reached a peak of 38.5 microgram/ml 15 minutes after 0.5 g intravenous administration. Urinary recovery rate unit 6 hours after the administration was 12.5%. Overall clinical efficacy of 6 cases of acute simple cystitis and 3 cases of chronic complicated cystitis was judged to be 83.3% and 33.3% respectively by a criterion proposed by the UTI Committee in Japan.
D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009287:Naphthyridines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D010403:Penicillin Resistance; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
D009287:Naphthyridines; C012122:apalcillin; D000667:Ampicillin